201. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.
- Author
-
Budd GT, Rankin C, Hutchins LF, Wong L, Petruska PJ, and Antman K
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents toxicity, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Sarcoma pathology, Sarcoma secondary, Topotecan administration & dosage, Topotecan toxicity, Antineoplastic Agents therapeutic use, Sarcoma drug therapy, Topotecan therapeutic use
- Abstract
Purpose: Based upon the hypothesis that prolonged exposure to the S-Phase specific agent topotecan would be more efficacious in the treatment of soft tissue sarcomas than a conventional 5-day schedule of the drug, the Southwest Oncology Group performed a Phase II trial of topotecan administered as a continuous infusion in adult patients with advanced soft tissue sarcomas., Methods: Patients who had received no prior chemotherapy for advanced disease were treated with topotecan at a dose of 0.50 mg/m2/day on days 1-21 of repeated 28 day cycles., Results: Twenty-two patients were enrolled on the study, of whom 21 were eligible. No objective responses were observed (95% confidence interval of 0-16%). The median survival was 12 months (95% confidence interval of 5-16 months)., Conclusions: We conclude that topotecan, given either according to a 5-day or a 21-day schedule, has minimal activity in the treatment of adult soft tissue sarcomas.
- Published
- 2002
- Full Text
- View/download PDF